Shionogi sues Hospira to block Doribax generic
In this story, Bill Baton, a partner in the Life Sciences and Commercial Litigation practices, discusses the legal issues that may influence the outcome of a Japanese pharmaceutical company’s lawsuit to stop another company from marketing a generic version of Doribax, an injectable antibiotic with the active ingredient doripenem. Bill explains that the lawsuit filed by Shionogi against Hospira Inc., appears to be an Abbreviated New Drug Application case brought under the Hatch-Waxman Act. Baton has significant experience with these types of cases.
To read the full article, click here.